p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages

  Wentzensen, Nicolas ^a   Fetterman, Barbara ^b   Castle, Philip E ^c,d   Schiffman, Mark ^a   Wood, Shannon N ^a   Stiemerling, Eric ^b   Tokugawa, Diane ^b   Bodelon, Clara ^a   Poitras, Nancy ^b   Lorey, Thomas ^b   Kinney, Walter ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c Global Coalition Against Cervical Cancer   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMATOXYLIN; KI 67 ANTIGEN; PROTEIN P16; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ARTICLE; BIOPSY; CANCER SCREENING; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL SIGNIFICANCE; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; CYTOTECHNOLOGIST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PATIENT REFERRAL; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; YOUDEN INDEX; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VIROLOGY;

ADULT; BIOMARKERS, TUMOR; CERVIX UTERI; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HUMANS; KI-67 ANTIGEN; MASS SCREENING; MIDDLE AGED; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REFERRAL AND CONSULTATION; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84951802471     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv257     Document Type: Article

References (26)

1. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368–383.
2. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147–172.
3. FDA approves first human papillomavirus test for primary cervical cancer screening. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm394773.htm
4. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
5. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8):dju153 doi:10.1093/jnci/dju153.
6. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–672.
7. Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6:1083–1098.
8. Wentzensen N. Triage of HPV-positive women in cervical cancer screening. Lancet Oncol. 2013;14(2):107–109.
9. Carozzi F, Confortini M, Dalla PP, et al. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2008;9(10):937–945.
10. Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/Ki-67 dual stained cytology: results of the PALMS study. J Natl Cancer Inst. 2013;105(20):1550–1557.
11. Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18(15):4154–4162.
12. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual stained cytology. Gynecol Oncol. 2011;121(3):505–509.
13. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113(3):595–600.
14. Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33(1):83–89.
15. Leisenring W, Alonzo T, Pepe MS. Comparisons of predictive values of binary medical diagnostic tests for paired designs. Biometrics. 2000;56(2):345–351.
16. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S28–S35.
17. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S1–S27.
18. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370(9601):1764–1772.
19. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–1101.
20. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–1588.
21. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–1394.
22. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880–890.
23. Wright TC Jr, Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R. Inter-laboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer. 2014;134(8):1835–1843.
24. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14(2):168–176.
25. Wentzensen N, Fetterman B, Tokugawa D, et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual stain cytology in cervical cancer screening. Cancer Cytopathol. 2014;122(12):914–920.
26. Grabe N, Lahrmann B, Pommerencke T, von Knebel DM, Reuschenbach M, Wentzensen N. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell Oncol. 2010;32(1–2):109–119.